Trial · NCT01204203
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
NCT01204203, Phase 2, Completed, University of Alabama at Birmingham; results first posted 2017-05-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901). Trials, record NCT01204203. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01204203
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
- NCT number
- NCT01204203
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Mesothelioma
- Interventions
- Zometa
- First posted
- 2010-09-17
- Last updated
- 2017-05-24
- Results first posted
- 2017-05-24
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor Response Rate Following Zoledronic Acid (Zometa) | Baseline up to 28 months or until progressive disease or death | The modified Response Evaluation Criteria in Solid Tumors Criteria (RECIST 2004) will be used for target lesions and assessed by CT scans. Complete Response (CR) is the disappearance of target lesions; Partial Response (PR) is greater than or equal to 30% reduction in the total tumor measurement; Stable Disease (SD) is the absence of response or progression; and Progressive Disease (PD) is a 20% increase in the total tumor measurement over nadir value or the appearance of new lesions. |
| Secondary | Progression Free Survival (PFS) | Baseline up to 28 months | Progression Free Survival is defined as the number of days from the day the subject started treatment to the day the subject experienced evidence of disease progression, as determined by radiological or clinical progression. |
| Secondary | Overall Survival (OS) | Baseline up to 28 months | Overall Survival is defined as the number of days from the day the subject started treatment to the day the subject experienced death or lost to follow-up. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Tumor Response Rate Following Zoledronic Acid (Zometa) | Baseline up to 28 months or until progressive disease or death | Participants with advanced malignant pleural mesothelioma. | percentage of responders | NUMBER |
| SECONDARY | Progression Free Survival (PFS) | Baseline up to 28 months | Participants with advanced malignant pleural mesothelioma. | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Baseline up to 28 months | Participants with advanced malignant pleural mesothelioma. | months | MEDIAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tumor Response Rate Following Zoledronic Acid (Zometa) | Zometa | 12.5 | percentage of responders | ||
| Progression Free Survival (PFS) | Zometa | 2 | Full Range 0.5 to 21 | Months | |
| Overall Survival (OS) | Zometa | 7 | Full Range 0.8 to 28 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Zoledronic Acid (Zometa) | 8 | |
| Overall Study | COMPLETED | Zoledronic Acid (Zometa) | 8 | |
| Overall Study | NOT COMPLETED | Zoledronic Acid (Zometa) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Zoledronic Acid (Zometa) | 0 | 8 |
| Total, other adverse events | Zoledronic Acid (Zometa) | 0 | 8 |
| Total, serious adverse events | Zoledronic Acid (Zometa) | 0 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01204203
GET https://conductscience.org/api/trials/v1/NCT01204203/registered